TODAY’S TRADEMARK – TAFINLAR

TAFINLAR® as a single agent is indicated for the treatment of patients with unrespectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. TAFINLAR, in combination with trametinib, is indicated for the treatment of patients with unrespectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate.

The TAFINLAR mark is filed in the category of Class 005 Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. . The legal correspondent for TAFINLAR trademark is Abel & Imray , BA1 2DA , UNITED KINGDOM.

Based on Novartis AG, the TAFINLAR trademark is used in the following business: Pharmaceutical and medicinal preparations and substances; vaccines.  Tafinlar and Mekinist are registered trademarks of the GSK group of companies.

The TAFINLAR  trademark was assigned  by the UK Intellectual Property Office (UKIPO). bearing registration number Australian Registration Numbers: TAFINLAR 50 mg capsules: AUST R 200922 TAFINLAR 75 mg capsules: AUST R 200936 on 14^th June, 2011.